Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NeuroSense Therapeutics Ltd. Warrant (NRSNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NRSNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -88.45% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.6 | 52 Weeks Range 0.10 - 1.06 | Updated Date 06/21/2025 |
52 Weeks Range 0.10 - 1.06 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -159.5% | Return on Equity (TTM) -2478.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 11925007 |
Shares Outstanding - | Shares Floating 11925007 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NeuroSense Therapeutics Ltd. Warrant
Company Overview
History and Background
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for neurodegenerative diseases. The warrants are related to the company's financing activities.
Core Business Areas
- Drug Development: Focuses on developing novel therapeutics for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease.
Leadership and Structure
The company has a management team focused on research, development, and clinical trials. Details on the organizational structure can be found in their filings.
Top Products and Market Share
Key Offerings
- PrimeC: NeuroSense's lead drug candidate, PrimeC, is being developed for ALS. It is currently in clinical trials. Market share data not applicable at this stage. Competitors: Amylyx Pharmaceuticals (AMYX), Biogen (BIIB).
Market Dynamics
Industry Overview
The neurodegenerative disease therapeutics market is large and growing due to an aging population. There is a high unmet need for effective treatments.
Positioning
NeuroSense is a smaller player in the biotechnology space, focusing on innovative therapies for underserved diseases. It aims to differentiate itself through novel drug candidates.
Total Addressable Market (TAM)
The market for ALS treatments is estimated at several billion USD annually. NeuroSense is positioned to capture a portion of this market if PrimeC is successful. Global amyotrophic lateral sclerosis (ALS) therapeutics market size was valued at USD 675.0 million in 2023 and is projected to reach USD 1.1 billion by 2032
Upturn SWOT Analysis
Strengths
- Novel drug candidate (PrimeC)
- Focus on high unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on successful clinical trial outcomes
- Small market capitalization
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion to other neurodegenerative diseases
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- AMYX
- BIIB
- ITCI
Competitive Landscape
NeuroSense faces significant competition from larger, more established pharmaceutical companies with greater resources and pipeline depth.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on funding and successful clinical trials.
Future Projections: Future growth is dependent on PrimeC.
Recent Initiatives: Focus is on advancing PrimeC through clinical trials.
Summary
NeuroSense is a high-risk, high-reward investment. The company is working to develop treatments for serious illnesses. If successful, it could generate value for shareholders. However, failure to achieve success in clinical trials could result in substantial losses. The small market capitalization makes it more sensitive to market fluctuations and financing risk is high.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Market research
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investing in biotechnology companies is inherently risky. Market share comparison is estimated and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NeuroSense Therapeutics Ltd. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-12-09 | Co-Founder, CEO & Director Mr. Alon Ben-Noon | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.neurosense-tx.com |
Full time employees 17 | Website https://www.neurosense-tx.com | ||
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.